EXTRACT: Clearly, the patentability standard for gene sequences and the commercial exclusivity available for such biotech inventions have been dramatically altered by the Federal Circuit's 'In re Kubin' decision.

QUOTE: "We again seem to be in a period... of frank hostility to patents and patent law from the Supreme Court." - biotech lawyer, Kevin E. Noonan
http://www.patentdocs.org/2009/04/is-everything-obvious.html

"This decision, along with 'In re Gleave'.., represents an ongoing trend reflected in the Federal Circuit's jurisprudence that makes patenting of classic biotechnology inventions more challenging."- Astrid R. Spain, patent law specialist and partner in the law firm McDermott Will & Emery
http://www.mondaq.com/article.asp?articleid=79724

Federal Circuit Limits Patentability Of Genetic Sequences
William L. Warren
IP Frontline, 15 May 2009 [extracts only]
http://www.cafezine.com/depts/article.asp?id=23110&deptid=4

On April 3, 2009, the U.S. Court of Appeals for the Federal Circuit issued 'In re Kubin' (Fed. Cir., No. 2008-1184), perhaps the most significant patent law decision affecting the genetic engineering industry in over a decade. At issue is the patentability of isolated genetic sequences, in this case encoding a previously identified, but unsequenced, protein.

Kubin's Impact On Gene Patenting

The Federal Circuit's decision in Kubin generally means that to the extent a protein has been previously identified, its nucleotide sequence is no longer patentable. The broader application of Kubin will include attempts to reject or invalidate claims directed to biotech inventions which claim an outcome of experimentation from among a range of expected results, even though not expressly predictable. There will undoubtedly be an increase in invalidity challenges to existing gene patents by those seeking to market generic and follow-on biologics prior to patent expiration, in view of the likelihood that pending regulatory legislation also passes. Clearly, the patentability standard for gene sequences and the commercial exclusivity available for such biotech inventions have been dramatically altered by the Federal Circuit's 'In re Kubin' decision.

For more information on this topic or related issues you can search the thousands of archived articles on the OCA website using keywords:

Become an OCA Member! Sign up below:

First Name
Last Name
Email
Email Preference	HTML EmailText Email
Phone
Street
Street 2
City
State	Select One... Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware D.C. Florida Georgia Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan Minnesota Mississippi Missouri Montana Nebraska Nevada New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Rhode Island South Carolina South Dakota Tennessee Texas Utah Vermont Virginia Washington West Virginia Wisconsin Wyoming Other
Zip
Country	United StatesAfghanistanAlbaniaAlgeriaAndorraAngolaAntigua and BarbudaArgentinaArmeniaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBhutanBoliviaBosnia and HerzegovinaBotswanaBrazilBruneiBulgariaBurkina FasoBurundiCambodiaCameroonCanadaCape VerdeCentral African RepublicChadChileChinaColombiaComorosCongoCongDemocratic Republic of theCosta RicaCroatiaCubaCyprusCzech RepublicIvory CoastDenmarkDjiboutiDominicaDominican RepublicEast TimorEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEthiopiaFijiFinlandFranceGabonGambiTheGeorgiaGermanyGhanaGreeceGrenadaGuatemalaGuineaGuinea-BissauGuyanaHaitiHondurasHungaryIcelandIndiaIndonesiaIranIraqIrelandIsraelItalyJamaicaJapanJordanKazakhstanKenyaKiribatiKoreNorthKoreSouthKuwaitKyrgyzstanLaosLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacedoniFormer Yugoslav Republic ofMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMauritaniaMauritiusMexicoMicronesiFederated States ofMoldovaMonacoMongoliaMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNew ZealandNicaraguaNigerNigeriaNorwayOmanPakistanPalauPanamaPapua New GuineaParaguayPeruPhilippinesPolandPortugalQatarRomaniaRussiaRwandaSaint Kitts and NevisSaint LuciaSaint Vincent and The GrenadinesSamoaSan MarinoSao Tome and PrincipeSaudi ArabiaSenegalSerbia and MontenegroSeychellesSierra LeoneSingaporeSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSpainSri LankaSudanSurinameSwazilandSwedenSwitzerlandSyriaTaiwanTajikistanTanzaniaThailandTogoTongaTrinidad and TobagoTunisiaTurkeyTurkmenistanTuvaluUgandaUkraineUnited Arab EmiratesUnited KingdomUruguayUzbekistanVanuatuVatican CityVenezuelaVietnamWestern SaharaYemenZambiaZimbabwe